Analysts expect Nabriva Therapeutics plc (NASDAQ:NBRV) to report ($0.21) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Nabriva Therapeutics’ earnings. The highest EPS estimate is ($0.19) and the lowest is ($0.24). Nabriva Therapeutics posted earnings per share of ($1.11) during the same quarter last year, which indicates a positive year-over-year growth rate of 81.1%. The firm is expected to announce its next quarterly earnings results on Thursday, March 10th.
On average, analysts expect that Nabriva Therapeutics will report full year earnings of ($1.10) per share for the current financial year, with EPS estimates ranging from ($1.12) to ($1.08). For the next financial year, analysts expect that the business will post earnings of ($0.56) per share, with EPS estimates ranging from ($0.67) to ($0.42). Zacks’ earnings per share calculations are a mean average based on a survey of research firms that follow Nabriva Therapeutics.
Separately, Zacks Investment Research upgraded Nabriva Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 target price on the stock in a research report on Saturday, November 13th.
In other Nabriva Therapeutics news, CEO Theodore R. Schroeder purchased 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 14th. The stock was bought at an average cost of $1.13 per share, with a total value of $56,500.00. Following the completion of the transaction, the chief executive officer now owns 226,875 shares of the company’s stock, valued at approximately $256,368.75. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.93% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Clear Creek Financial Management LLC bought a new position in shares of Nabriva Therapeutics in the second quarter worth $27,000. Advisor Group Holdings Inc. raised its position in Nabriva Therapeutics by 5,200.0% during the third quarter. Advisor Group Holdings Inc. now owns 26,500 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 26,000 shares in the last quarter. Millennium Management LLC purchased a new stake in Nabriva Therapeutics during the second quarter valued at about $42,000. Two Sigma Securities LLC purchased a new stake in Nabriva Therapeutics during the third quarter valued at about $48,000. Finally, Geode Capital Management LLC increased its holdings in shares of Nabriva Therapeutics by 102.9% in the third quarter. Geode Capital Management LLC now owns 42,738 shares of the biotechnology company’s stock worth $50,000 after buying an additional 21,672 shares during the period. 0.71% of the stock is owned by institutional investors and hedge funds.
Nabriva Therapeutics Company Profile
Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and commercialization of novel anti-infective agents to treat serious infections. Its product pipeline includes Lefamulin, and CONTEPO. The company was founded in October 2005 and is headquartered in Dublin, Ireland.
Featured Article: Using other technical indicators with support levels
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.